V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis
This is an 18 week (2 weeks run-in, 16 weeks double blind) trial, to determine if an antiviral drug, valacyclovir (Valtrex) is helpful in treating the symptoms of psychosis, a form of a mental disorder.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||V3: Vancouver-Victoria Valacyclovir Trial for Early Psychosis|
- Unspecified [ Time Frame: Unspecified ] [ Designated as safety issue: No ]
|Study Start Date:||September 2005|
|Study Completion Date:||September 2009|
|Primary Completion Date:||September 2009 (Final data collection date for primary outcome measure)|
Drug: Valacyclovir (Valtrex)
There is evidence that some of the symptoms of psychosis may be related to past infection with common viruses.
Researchers are looking to recruit a total of 100 subjects with evidence in the past, of exposure to at least 1 of 3 viruses. The viruses include herpes type 1 (HSV-1, which causes cold sores of the lip and has affected about 6/10 people in Vancouver), herpes type 2 (HSV-2 which causes genital sores, and has affected less than 1/10 people in Vancouver) and cytomegalovirus (CMV, which causes few symptoms but has affected 8/10 people in Vancouver). People who have been infected with these viruses in the past develop antibodies in the blood. The antibodies can be measured in blood, and are a test of whether or not there was infection in the past, and possibly affecting the symptoms of psychosis.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00175513
|Canada, British Columbia|
|Eric Martin Pavilion|
|Victoria, British Columbia, Canada|
|Peace Arch Hospital|
|White Rock, British Columbia, Canada|
|Principal Investigator:||William Honer, MD||University of British Columbia|